Compare SLDB & FEIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLDB | FEIM |
|---|---|---|
| Founded | 2013 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.7M | 722.9M |
| IPO Year | 2017 | 1994 |
| Metric | SLDB | FEIM |
|---|---|---|
| Price | $5.92 | $64.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 2 |
| Target Price | $18.71 | ★ $95.50 |
| AVG Volume (30 Days) | ★ 1.3M | 277.6K |
| Earning Date | 11-02-2026 | 12-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.97 | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | $8,094,000.00 | ★ $63,227,000.00 |
| Revenue This Year | N/A | $30.80 |
| Revenue Next Year | N/A | $26.18 |
| P/E Ratio | ★ N/A | $150.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $26.05 |
| 52 Week High | $11.45 | $89.76 |
| Indicator | SLDB | FEIM |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 37.94 |
| Support Level | $5.38 | $62.33 |
| Resistance Level | $7.26 | $64.99 |
| Average True Range (ATR) | 0.42 | 4.16 |
| MACD | 0.06 | -1.79 |
| Stochastic Oscillator | 30.72 | 19.79 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.